Rituximab does not reset defective early B cell tolerance checkpoints

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 282-287

  Chamberlain, Nicolas ^a   Massad, Christopher ^a   Oe, Tyler ^a   Cantaert, Tineke ^a   Herold, Kevan C ^a   Meffre, Eric ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RITUXIMAB; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOLESCENT; ADULT; AGED; ANTI B CELL THERAPY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL THERAPY; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNE DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIPLE SCLEROSIS; PANCREAS ISLET CELL FUNCTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; YOUNG ADULT; DRUG EFFECTS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE DEPLETION; PHYSIOLOGY;

B-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE DEPLETION; RECEPTORS, ANTIGEN, B-CELL; RITUXIMAB;

EID: 84956611427     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83840     Document Type: Article

References (20)

1. Serreze DV, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Igmunull mice. J Exp Med. 1996;184(5):2049-2053.
2. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, Tisch RM. B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol. 1998;161(8):3912-3918.
3. Hu CY, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest. 2007;117(12):3857-3867.
4. Menard L, et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest. 2011;121(9):3635-3644.
5. Martin S, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med. 2001;345(14):1036-1040.
6. Winkelstein JA, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore). 2006;85(4):193-202.
7. Pescovitz MD, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143-2152.
8. Pescovitz MD, et al. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care. 2014;37(2):453-459.
9. Edwards JCW, et al. Efficacy of B cell-targeted therapy with Rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581.
10. Hauser SL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688.
11. Herold KC, et al. Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol. 2011;187(4):1998-2005.
12. Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491-502.
13. van Zelm MC, Szczepanski T, van der Burg M, van Dongen JJ. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. J Exp Med. 2007;204(3):645-655.
14. Kinnunen T, et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest. 2013;123(6):2737-2741.
15. Samuels J, Ng YS, Coupillaud C, Paget D, Meffre E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med. 2005;201(10):1659-1667.
16. Yurasov S, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005;201(5):703-711.
17. Meffre E. The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Ann N Y Acad Sci. 2011;1246:1-10.
18. Kinnunen T, et al. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood. 2013;121(9):1595-1603.
19. Arechiga AF, et al. Cutting edge: The PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol. 2009;182(6):3343-3347.
20. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. New Engl J Med. 2011;365(17):1612-1623.